170 related articles for article (PubMed ID: 30661303)
1. Elevated serum HER-2 predicts poor prognosis in breast cancer and is correlated to ADAM10 expression.
Zheng H; Zhong A; Xie S; Wang Y; Sun J; Zhang J; Tong Y; Chen M; Zhang G; Ma Q; Kai J; Guo L; Lu R
Cancer Med; 2019 Feb; 8(2):679-685. PubMed ID: 30661303
[TBL] [Abstract][Full Text] [Related]
2. Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells.
Liu PC; Liu X; Li Y; Covington M; Wynn R; Huber R; Hillman M; Yang G; Ellis D; Marando C; Katiyar K; Bradley J; Abremski K; Stow M; Rupar M; Zhuo J; Li YL; Lin Q; Burns D; Xu M; Zhang C; Qian DQ; He C; Sharief V; Weng L; Agrios C; Shi E; Metcalf B; Newton R; Friedman S; Yao W; Scherle P; Hollis G; Burn TC
Cancer Biol Ther; 2006 Jun; 5(6):657-64. PubMed ID: 16627989
[TBL] [Abstract][Full Text] [Related]
3. Proteolytic cleavage of amyloid precursor protein by ADAM10 mediates proliferation and migration in breast cancer.
Tsang JYS; Lee MA; Chan TH; Li J; Ni YB; Shao Y; Chan SK; Cheungc SY; Lau KF; Tse GMK
EBioMedicine; 2018 Dec; 38():89-99. PubMed ID: 30470613
[TBL] [Abstract][Full Text] [Related]
4. High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients.
Kong Y; Dai S; Xie X; Xiao X; Lv N; Guo J; Li L; Jia W; Zhang Y; Liu W; Wei W; Xie X
J Cancer Res Clin Oncol; 2012 Feb; 138(2):275-84. PubMed ID: 22116318
[TBL] [Abstract][Full Text] [Related]
5. ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer.
Feldinger K; Generali D; Kramer-Marek G; Gijsen M; Ng TB; Wong JH; Strina C; Cappelletti M; Andreis D; Li JL; Bridges E; Turley H; Leek R; Roxanis I; Capala J; Murphy G; Harris AL; Kong A
Oncotarget; 2014 Aug; 5(16):6633-46. PubMed ID: 24952873
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer.
Ardavanis A; Kountourakis P; Kyriakou F; Malliou S; Mantzaris I; Garoufali A; Yiotis I; Scorilas A; Baziotis N; Rigatos G
Oncologist; 2008 Apr; 13(4):361-9. PubMed ID: 18448549
[TBL] [Abstract][Full Text] [Related]
7. Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer.
Lee SB; Lee JW; Yu JH; Ko BS; Kim HJ; Son BH; Gong G; Lee HJ; Kim SB; Jung KH; Ahn JH; Lee W; Sung J; Ahn SH
BMC Cancer; 2014 Dec; 14():929. PubMed ID: 25491647
[TBL] [Abstract][Full Text] [Related]
8. Outcome prediction values of soluble human epidermal growth factor receptor-2 extracellular domain in metastatic breast cancer.
Shao X; Wang X; Xu X; Feng J; Han M; Zhang H; Chen ZH; Wang S; Zang YM; Huang P; Jin H; Wang X
Int J Clin Exp Pathol; 2014; 7(3):1108-13. PubMed ID: 24696727
[TBL] [Abstract][Full Text] [Related]
9. Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer.
Di Gioia D; Dresse M; Mayr D; Nagel D; Heinemann V; Stieber P
Clin Chim Acta; 2015 Feb; 440():16-22. PubMed ID: 25444743
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
Müller V; Witzel I; Lück HJ; Köhler G; von Minckwitz G; Möbus V; Sattler D; Wilczak W; Löning T; Jänicke F; Pantel K; Thomssen C
Breast Cancer Res Treat; 2004 Jul; 86(1):9-18. PubMed ID: 15218357
[TBL] [Abstract][Full Text] [Related]
11. A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression.
Reix N; Malina C; Chenard MP; Bellocq JP; Delpous S; Molière S; Sevrin A; Neuberger K; Tomasetto C; Mathelin C
Breast Cancer Res Treat; 2016 Nov; 160(2):249-259. PubMed ID: 27709352
[TBL] [Abstract][Full Text] [Related]
12. Shed HER2 surrogacy evaluation in primary breast cancer patients: a study assessing tumor tissue HER2 expression at both extracellular and intracellular levels.
Fabricio ASC; Michilin S; Zancan M; Agnolon V; Peloso L; Dittadi R; Scapinello A; Ceccarelli C; Gion M
Scand J Clin Lab Invest; 2019 Jul; 79(4):260-267. PubMed ID: 30982358
[TBL] [Abstract][Full Text] [Related]
13. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy.
Harris LN; Liotcheva V; Broadwater G; Ramirez MJ; Maimonis P; Anderson S; Everett T; Harpole D; Moore MB; Berry DA; Rizzeri D; Vredenburgh JJ; Bentley RC
J Clin Oncol; 2001 Mar; 19(6):1698-706. PubMed ID: 11250999
[TBL] [Abstract][Full Text] [Related]
14. Tissue expression and serum levels of the oncoprotein HER-2/neu in 157 primary breast tumours.
Pallud C; Guinebretiere JM; Guepratte S; Hacene K; Neumann R; Carney W; Pichon MF
Anticancer Res; 2005; 25(2B):1433-40. PubMed ID: 15865102
[TBL] [Abstract][Full Text] [Related]
15. Relationships between serum HER2 ECD, TIMP-1 and clinical outcomes in Taiwanese breast cancer.
Tsai HP; Chen SC; Chien HT; Jan YY; Chao TC; Chen MF; Hsieh LL
World J Surg Oncol; 2012 Feb; 10():42. PubMed ID: 22339939
[TBL] [Abstract][Full Text] [Related]
16. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer.
Carney WP; Neumann R; Lipton A; Leitzel K; Ali S; Price CP
Clin Chem; 2003 Oct; 49(10):1579-98. PubMed ID: 14500583
[TBL] [Abstract][Full Text] [Related]
17. Circulating Her-2/neu extracellular domain in breast cancer patients-correlation with prognosis and clinicopathological parameters including steroid receptor, Her-2/neu receptor coexpression.
Barić M; Kulić A; Sirotković-Skerlev M; Dedić Plavetić N; Vidović M; Horvatić-Herceg G; Vrbanec D
Pathol Oncol Res; 2015 Jul; 21(3):589-95. PubMed ID: 25367073
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival.
Ludovini V; Gori S; Colozza M; Pistola L; Rulli E; Floriani I; Pacifico E; Tofanetti FR; Sidoni A; Basurto C; Rulli A; Crinò L
Ann Oncol; 2008 May; 19(5):883-90. PubMed ID: 18187484
[TBL] [Abstract][Full Text] [Related]
19. The extracellular domain of Her2 in serum as a biomarker of breast cancer.
Perrier A; Gligorov J; Lefèvre G; Boissan M
Lab Invest; 2018 Jun; 98(6):696-707. PubMed ID: 29491426
[TBL] [Abstract][Full Text] [Related]
20. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
Mazouni C; Hall A; Broglio K; Fritsche H; Andre F; Esteva FJ; Hortobagyi GN; Buzdar AU; Pusztai L; Cristofanilli M
Cancer; 2007 Feb; 109(3):496-501. PubMed ID: 17149760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
